Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition
Open Access
- 22 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (9), 2533-2548
- https://doi.org/10.1158/1078-0432.ccr-20-3872
Abstract
Purpose:. Covalent inhibitors of KRASG12C specifically target tumors driven by this form of mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance. Although several combination strategies have been shown to improve efficacy of KRASG12C inhibitors (KRASi), underlying mechanisms and predictive strategies for patient enrichment are less clear.Experimental Design:. We performed mass spectrometry–based phosphoproteomics analysis in KRASG12C cell lines after short-term treatment with ARS-1620. To understand signaling diversity and cell type–specific markers, we compared proteome and phosphoproteomes of KRASG12C cells. Gene expression patterns of KRASG12C cell lines and lung tumor tissues were examined.Results:. Our analysis suggests cell type–specific perturbation to ERBB2/3 signaling compensates for repressed ERK and AKT signaling following ARS-1620 treatment in epithelial cell type, and this subtype was also more responsive to coinhibition of SHP2 and SOS1. Conversely, both high basal and feedback activation of FGFR or AXL signaling were identified in mesenchymal cells. Inhibition of FGFR signaling suppressed feedback activation of ERK and mTOR, while AXL inhibition suppressed PI3K pathway. In both cell lines and human lung cancer tissues with KRASG12C, we observed high basal ERBB2/3 associated with epithelial gene signatures, while higher basal FGFR1 and AXL were observed in cells/tumors with mesenchymal gene signatures.Conclusions:. Our phosphoproteomic study identified cell type–adaptive responses to KRASi. Markers and targets associated with ERBB2/3 signaling in epithelial subtype and with FGFR1/AXL signaling in mesenchymal subtype should be considered in patient enrichment schemes with KRASi.Keywords
Other Versions
Funding Information
- State of Florida Bankhead Coley (5BC07)
- H. Lee Moffitt Cancer Center and Research Institute (P30-CA076292)
This publication has 49 references indexed in Scilit:
- Fibroblast Growth Factor Receptor Like-1 (FGFRL1) Interacts with SHP-1 Phosphatase at Insulin Secretory Granules and Induces Beta-cell ERK1/2 Protein ActivationJournal of Biological Chemistry, 2013
- RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activationBiochemical Journal, 2012
- Negative Feedback and Adaptive Resistance to the Targeted Therapy of CancerCancer Discovery, 2012
- erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell linesBreast Cancer Research, 2011
- KRAS Mouse Models: Modeling Cancer Harboring KRAS MutationsGenes & Cancer, 2011
- Effect of Collision Energy Optimization on the Measurement of Peptides by Selected Reaction Monitoring (SRM) Mass SpectrometryAnalytical Chemistry, 2010
- The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switchCellular Signalling, 2009
- Oncogenic K-ras “addiction” and synthetic lethalityCell Cycle, 2009
- Epidermal Growth Factor Receptor Phosphorylation Sites Ser991 and Tyr998 Are Implicated in the Regulation of Receptor Endocytosis and Phosphorylations at Ser1039 and Thr1041Molecular & Cellular Proteomics, 2009
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantificationNature Biotechnology, 2008